Goldschmidt H - Search Results

1

IL-10 inducible CD8⁺ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells.

Plaumann J, Engelhardt M, Awwad MHS, Echchannaoui H, Amman E, Raab MS, Hillengass J, Halama N, Neuber B, Müller-Tidow C, Goldschmidt H, Hundemer M. Plaumann J, et al. Among authors: goldschmidt h. Cancer Immunol Immunother. 2018 Nov;67(11):1695-1707. doi: 10.1007/s00262-018-2230-0. Epub 2018 Aug 20. Cancer Immunol Immunother. 2018. PMID: 30128739 Free PMC article.

2

Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.

Choi C, Witzens M, Bucur M, Feuerer M, Sommerfeldt N, Trojan A, Ho A, Schirrmacher V, Goldschmidt H, Beckhove P. Choi C, et al. Among authors: goldschmidt h. Blood. 2005 Mar 1;105(5):2132-4. doi: 10.1182/blood-2004-01-0366. Epub 2004 Nov 23. Blood. 2005. PMID: 15561890 Free article.

3

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H. Perz JB, et al. Among authors: goldschmidt h. Br J Haematol. 2004 Dec;127(5):543-51. doi: 10.1111/j.1365-2141.2004.05232.x. Br J Haematol. 2004. PMID: 15566357 Free article. Clinical Trial.

4

Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers.

Nosàs-Garcia S, Moehler T, Wasser K, Kiessling F, Bartl R, Zuna I, Hillengass J, Goldschmidt H, Kauczor HU, Delorme S. Nosàs-Garcia S, et al. Among authors: goldschmidt h. J Magn Reson Imaging. 2005 Jul;22(1):154-62. doi: 10.1002/jmri.20349. J Magn Reson Imaging. 2005. PMID: 15971177

5

Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.

Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, Benner A, Raab MS, Theil AC, Moos M, Goldschmidt H, Bartram CR, Jauch A. Cremer FW, et al. Among authors: goldschmidt h. Genes Chromosomes Cancer. 2005 Oct;44(2):194-203. doi: 10.1002/gcc.20231. Genes Chromosomes Cancer. 2005. PMID: 16001433

6

Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.

Lotz C, Mutallib SA, Oehlrich N, Liewer U, Ferreira EA, Moos M, Hundemer M, Schneider S, Strand S, Huber C, Goldschmidt H, Theobald M. Lotz C, et al. Among authors: goldschmidt h. J Immunol. 2005 Jul 15;175(2):1301-9. doi: 10.4049/jimmunol.175.2.1301. J Immunol. 2005. PMID: 16002735

7

Risk stratification in cardiac amyloidosis: novel approaches.

Kristen AV, Meyer FJ, Perz JB, Schonland SO, Hundemer M, Hegenbart U, Singer R, Schnabel PA, Sack FU, Goldschmidt H, Katus HA, Dengler TJ. Kristen AV, et al. Among authors: goldschmidt h. Transplantation. 2005 Sep 27;80(1 Suppl):S151-5. doi: 10.1097/01.tp.0000187111.00076.1a. Transplantation. 2005. PMID: 16286895 Review.

8

Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis.

Schonland SO, Perz JB, Hundemer M, Hegenbart U, Kristen AV, Hund E, Dengler TJ, Beimler J, Zeier M, Singer R, Linke RP, Ho AD, Goldschmidt H. Schonland SO, et al. Among authors: goldschmidt h. Transplantation. 2005 Sep 27;80(1 Suppl):S160-3. doi: 10.1097/01.tp.0000186902.57687.8d. Transplantation. 2005. PMID: 16286897

9

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, Cremer F, Kleist C, Terness P, Belle S, Ho AD, Goldschmidt H, Klein B, Christensen O. Hundemer M, et al. Among authors: goldschmidt h. Exp Hematol. 2006 Apr;34(4):486-96. doi: 10.1016/j.exphem.2006.01.008. Exp Hematol. 2006. PMID: 16569595 Free PMC article.

10

Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).

Li G, Hundemer M, Wolfrum S, Ho AD, Goldschmidt H, Witzens-Harig M. Li G, et al. Among authors: goldschmidt h. Ann Hematol. 2006 Sep;85(9):583-90. doi: 10.1007/s00277-006-0137-x. Epub 2006 May 23. Ann Hematol. 2006. PMID: 16718496

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

841 results

Search Page

Filters